Product Information

BENICAR HCT 20-12.5 MG TABLET is a brand product labeled by Cosette Pharmaceuticals, Inc., priced at $11.3168 per EA under NDC 00713086330. Its NADAC has been published 171 times since Apr 19, 2023.

FDA first approved this application on Jun 5, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

BENICAR HCT 20-12.5 MG TABLET

olmesartan medoxomil-hydrochlorothiazide
$11.3168per EA

Strength

12.5; 20 mg/1; mg/1

NDC

00713086330

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

7/22/2026

Approval Type

New Drug (NDA)

FDA Application

NDA021532

FDA Approved

6/5/2003

TE Code

AB

On Market Since

9/1/2022

Pharmacological Classes

Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker
Increased Diuresis
Thiazide Diuretic
Thiazides

Price Statistics

The NADAC for BENICAR HCT 20-12.5 MG TABLET has been published 171 times since Apr 19, 2023, and over the history we have for it it has risen 32.9%. The table below summarizes its recorded NADAC range and movement.

Current price$11.3168 per EA
All-time high$11.3168 (Jul 22, 2026)
All-time low$8.5158 (Apr 19, 2023)
52-week high$11.3168
52-week low$10.2739
Median price$10.2753
Average price$10.0338
Largest weekly change+10.0% (Sep 25, 2024)
Weeks tracked171
Tracking sinceApr 19, 2023

Price History

1W

N/A

1M

N/A

3M

0.0%

6M

+0.6%

1Y

+10.2%

3Y

+32.9%

5Y

N/A

All

+32.9%

Last surveyed Jul 22, 2026 — this NDC no longer appears in the current weekly NADAC file.

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the olmesartan medoxomil-hydrochlorothiazide market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of BENICAR HCT 20-12.5 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for BENICAR HCT 20-12.5 MG TABLET, manufactured by Cosette Pharmaceuticals, Inc., is $11.3168 per EA (NDC 00713086330), effective Jul 22, 2026.

How has the price of BENICAR HCT 20-12.5 MG TABLET changed over time?

Over the history we have for it, the NADAC for BENICAR HCT 20-12.5 MG TABLET has risen 32.9%. It has been tracked across 171 weekly CMS publications since Apr 19, 2023.

What are the highest and lowest recorded NADAC prices for BENICAR HCT 20-12.5 MG TABLET?

Since Apr 19, 2023, the NADAC for BENICAR HCT 20-12.5 MG TABLET has ranged from a low of $8.5158 (Apr 19, 2023) to a high of $11.3168 (Jul 22, 2026), with a median of $10.2753 per EA.

Are there cheaper alternatives to BENICAR HCT 20-12.5 MG TABLET?

No other NADAC-published product currently shares the active ingredient and strength of BENICAR HCT 20-12.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures BENICAR HCT 20-12.5 MG TABLET?

BENICAR HCT 20-12.5 MG TABLET (NDC 00713086330) is labeled by Cosette Pharmaceuticals, Inc., and CMS classifies it as a brand product.